Definium (DFTX) CMO Daniel Karlin Sells 10,035 Shares

What Happened
Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), sold 10,035 common shares on 2026-06-25 at $45.03 per share, totaling $451,876. The sale was executed to satisfy withholding tax obligations related to the settlement of vested restricted stock units (RSUs).

Key Details

• Transaction date: 2026-06-25; filing date: 2026-06-26 (file appears timely).
• Transaction type/code: Sale (S); 10,035 shares sold at $45.03 each, total proceeds ≈ $451,876.
• Footnote: Sale represents shares sold to satisfy tax withholding on vested RSUs pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted June 14, 2022 (Footnote F1).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No indication in the excerpt that this is a late (L) filing or that the insider is a 10% owner.

Context
Sell-to-cover transactions tied to RSU vesting are routine tax-withholding actions and are often executed under pre-established 10b5-1 plans; they generally do not signal a change in an insider’s view of the company. Purchases typically carry more weight as positive insider signals; this filing documents a standard tax-related sale.